Pediatric Exclusivity Changes Should Be Minimal In Reauthorization - FDA

FDA should consider supporting "wild card" pediatric exclusivity which would allow companies to apply patent extensions to a product of their choice in return for performing needed pediatric research, Oncologic Drugs Advisory Committee member Henry Friedman, MD, Duke University Medical Center, suggested.